In an interview with Consultant360, study author Ying-Ying Leung, MD, MBChB said this about the treatment strategies for patients with PsA who do not respond to tumor necrosis factor inhibitors: “The decision for a change of treatment needs to be individualized, taking into consideration articular and extra-articular manifestations of the disease, comprehensive assessment of disease burden, patient profile, and _____.”